Breakthrough for AlzeCure in the development of drugs for nerve pain
AlzeCure Pharma shows positive results from its clinical study with a new non-opioid drug candidate developed against peripheral neuropathic pain.
New data from AlzeCure’s phase IIa study show that the drug candidate ACD440 has a significant analgesic effect on pain induced by cold and heat.
– The medical need in this area is immense, not least to find alternatives to opioids. Neuropathic pain is the single largest market segment in pain management, generating over $11 billion in annual revenues. Up to 80 percent of all patients do not get a satisfactory effect with their current treatments, said AlzeCure Pharma’s CEO Martin Jönsson.
AlzeCure is among a handful of companies in the world that develop drugs that target the TRPV1 receptor, whose discovery was awarded the 2021 Nobel Prize in Medicine. The goal is to help people who suffer from nerve pain. In many cases today, there is no other effective treatment available than opioids, which both numb the whole body and can lead to addiction and substance abuse.
Campus day 2024
Campus Day is for all students at Campus Flemingsberg. Come and meet students from Karolinska Institutet, KTH, the Red Cross University College, SMI, and Södertörn University. There will be performances and speeches on stage. Enjoy music, play ping-pong, or take the campus quiz and get a lunch! (Limited availability)
Irma Alert and The Digital Immune System: Winners of the Flemingsberg Science Award STARTUP 2024
Sweden's children and youth are not doing well. Mental health issues, increasing neuropsychiatric disorders, and sociocultural confusion, partly caused by social media, are on the rise. As a result, the level of knowledge among young people is declining, with reading comprehension and mathematics being particularly problematic areas. Irma Alert, the winner of the Flemingsberg Science Award, wants to change this.
Maria Eriksdotter: Dean, Leader and Enthusiast who strengthened the sense of community in Flemingsberg
After her four years as dean, Maria has successfully put KI South and Flemingsberg on the map. Maria is an enthusiast who has driven KI South forward in recent years with great commitment. Now that she is leaving her role as dean of Karolinska Institutet, we at the Flemingsberg Science Foundation reflect on all the progress and achievements she has made.
